Home/Filings/4/0001209191-23-053344
4//SEC Filing

Byam Rebecca 4

Accession 0001209191-23-053344

CIK 0001828673other

Filed

Oct 22, 8:00 PM ET

Accepted

Oct 23, 4:44 PM ET

Size

7.4 KB

Accession

0001209191-23-053344

Insider Transaction Report

Form 4
Period: 2023-10-19
Byam Rebecca
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2023-10-19$0.14/sh+47,249$6,615621,195 total
  • Exercise/Conversion

    Stock Option Grant (Right to Buy)

    2023-10-1947,2490 total
    Exercise: $0.14Exp: 2029-12-19Common Stock (47,249 underlying)
Footnotes (1)
  • [F1]These option shares were part of a stock option grant covering 135,000 shares of common stock. 20% of the total shares subject to the stock option grant vested on October 10, 2020; 20% of the total shares subject to the stock option grant vested on October 10, 2021; 25% of the total shares subject to the stock option grant vested on October 10, 2022; and 35% of the total shares subject to the stock option grant vested on October 10, 2023, subject to her continuous service through the applicable vesting date. The option is subject to additional vesting acceleration pursuant to her Employment Agreement.

Issuer

HCW Biologics Inc.

CIK 0001828673

Entity typeother

Related Parties

1
  • filerCIK 0001866256

Filing Metadata

Form type
4
Filed
Oct 22, 8:00 PM ET
Accepted
Oct 23, 4:44 PM ET
Size
7.4 KB